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Curcumin encapsulated in mesoporous silica nanoparticles 5 
showed improved solubility, in vitro release profile and 
significantly enhanced cell cytotoxicity compared to the pure 
drug.  
Curcumin, a diferuloylmethane obtained from the rhizomes of the 
plant Curcuma longa,1 is commonly used as a spice, dye and 10 
traditional medicine in Indian and Chinese culture (see Scheme 
1A for its structure). Curcumin possesses a range of 
pharmacological activities such as antiseptic, anti-inflammatory, 
antioxidant, antiarthritic, and anticancer functions.2 It has been 
found that curcumin inhibits the viability and proliferation in a 15 
variety of human cancer cell lines including gastrointestinal 
cancers, genitourinary cancers, breast cancer, ovarian cancer, 
lung cancer, melanoma, and sarcoma.3, 4 Despite of its 
advantages, the clinical application of curcumin is stalled due to 
its poor aqueous solubility leading to poor bioavailability.5  20 
Several curcumin delivery systems such as surfactant complex, 
liposomes, hydrogels, and polymeric nanoparticles have been 
developed but suffer from synthesis complexity and poor 
biological stability.6-8 Compared to the organic counterparts, 
mesoporous silica nanoparticles (MSNs) with rigid inorganic 25 
frameworks have attracted increasing attention as drug delivery 
carriers9, 10 owing to their unique properties.11 Previously, 
curcumin was encapsulated in cetyltrimethylammonium bromide 
(CTAB) micelle followed by silica coating,12 or used as a model 
drug to test its pH-dependent in vitro release behavior in modified 30 
porous silica materials.13,14 It is noted that curcumin undergoes 
rapid degradation at pH > 7.70 (condition used in in vitro release 
studies).15 Moreover, CTAB has shown toxicity in cell studies.16, 
17 It is concluded that the great potential of MSNs in curcumin 
formulation, i.e.; using nanopores with high pore volumes as the 35 
reservoir for drug loading and controlled release, and using the 
desired particle size for cellular delivery, is yet to be exploited. 
In this work, for the first time, we demonstrate that curcumin 
can be successfully encapsulated in the nanopores of MSNs 
through a hydrogen-bonding model (Scheme 1B) leading to 40 
significantly higher cell cytotoxicity. Compared to pure drug, the 
curcumin loaded inside MSNs shows enhanced solubility, 
sustained release profile, and improved cell cytotoxicity towards 
SCC-25, a skin cancer cell line. It is shown that the cellular 
toxicity is associated with the inhibition of polycomb group 45 
(PcG) onco-proteins, which are highly expressed in cancer cells 
and responsible for the cell proliferation and survival.18, 19 The 
curcumin encapsulated in MSNs sufficiently knocks down the 
 
Scheme 1 Schematic representation comparing treatment of SCC-50 
25 cell with pure curcumin (A) and curcumin encapsulated 
MCM-41 (B) displaying higher cytotoxic effect by curcumin 
encapsulated MCM-41. 
expression level of PcG proteins, thus the growth and 
transformation of cancer cells are inhibited.20  55 
 MCM-4121 type MSNs were synthesized and curcumin (CUR) 
was encapsulated into calcined MCM-41 (MCM-41-CUR)  by a 
simple rotary evaporatory (Rotavap) technique (See Electronic 
Supplementary Information, ESI). For comparison the physical 
mixture of MCM-41 and curcumin (MCM-41-CUR PM) was also 60 
prepared.  
 The X-ray diffraction (XRD) pattern of calcined MCM-41 
(Fig. S1A) shows three well resolved diffractions at 2θ of 2.68, 
4.63 and 5.34° with a reciprocal d-spacing ratio close to 1: √3: 2, 
which can be indexed as 100, 110 and 200 reflections of an 65 
ordered two-dimensional (2D) hexagonal mesostructure (p6mm). 
MCM-41-CUR displayed XRD pattern similar to that of MCM-
41 demonstrating retention of the ordered structure after the 
curcumin encapsulation. Transmission electron microscopy 
(TEM) image of MCM-41 shows the typical well-ordered 70 
hexagonal structure (Fig. S1B) and mean size of 164 nm 
(PDI=0.23) and 190 nm (PDI=0.31)  for MCM-41 and MCM-41-
CUR respectively (Fig. S1C). 
 The N2 adsorption-desorption isotherms of MCM-41 and 
MCM-41-CUR (Fig. S2A) exhibited typical type IV isotherm and 75 
a steep capillary condensation step occurring at a relative pressure 
(P/P0) range of 0.2-0.4. Compared to MCM-41, the surface area 
and pore volume of MCM-41-CUR decrease (Table S1). From 
the pore size distribution curves it is shown that the pore size of 
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MCM-41-CUR decreases from 2.23 to 2.12 nm (Fig. S2B), indicating that CUR forms nano-sized aggregates in the pores.  
 
Fig. 1 In vitro cytotoxicity of pure curcumin, MCM-41-CUR and MCM-41-CUR PM in SCC-25 cell line after 24, 48 and 72h (A). CTL, 
C1, C2 and C3 denote the control group, curcumin equivalent dose of 15 ppm, 30 ppm and 45 ppm respectively used in the cell 5 
cytotoxicity experiment.  Protein expression studies using Western blot analysis for pure curcumin, MCM-41-CUR and MCM-41 (B). 
 Thermogravimetric analysis (TGA) shows 17% of curcumin 
encapsulation for MCM-41-CUR (Fig. S3A), indicating a high 
efficiency (85%) of the Rotavap process used for curcumin 
encapsulation, in accordance with a previous report.22 For 10 
comparison, MCM-41-CUR PM sample shows a CUR weight 
loss of 20% identical to the feed ratio in the physical mixing. 
Differential scanning calorimetry (DSC) analysis was performed 
to determine the crystallisation behaviour of curcumin in MCM-
41-CUR and MCM-41-CUR PM (Fig. S3B). Pure curcumin 15 
clearly displays a sharp melting point peak at 176 °C. A small 
peak is observed for MCM-41-CUR PM indicating existence of 
curcumin’s crystalline structure after physical mixing. However, 
such a peak cannot be found in MCM-41-CUR, suggesting 
curcumin has been loaded successfully in the pores of MCM-41 20 
as nano-sized aggregates.23, 24  
 Fourier transform infrared (FTIR) analysis was performed to 
study the interaction between curcumin and MCM-41. To 
observe the information clearly, only regions of interest are 
shown in Figure S4. MCM-41 exhibits one typical peak at 3745 25 
cm-1 assigned to isolated silanols (ν(O-H)) whereas CUR displays 
a sharp peak at 3507 cm-1 and a broad peak at 3293 cm-1 (–OH 
group vibrations without and with intermolecular hydrogen 
bonding, respectively).25  The above three peaks can be observed 
in the spectrum of MCM-41-CUR PM, however, not in MCM-30 
41-CUR. Instead a new broad peak centered at 3428 cm-1 
(Fig.S4A) can be seen in MCM-41-CUR due to intermolecular 
hydrogen bonding between isolated silanol and enolic hydroxyl 
group 26 (Scheme 1B). Additionally, the other typical CUR bands 
are also found in MCM-41-CUR (Figs. S4A and B).  35 
 Solubility of curcumin was determined by preparing saturated 
solution of CUR, MCM-41-CUR and MCM-41-CUR PM in 
water to reach the equilibrium concentration. Curcumin solubility 
was increased by 71% in MCM-41-CUR (0.53 µg/ml) compared 
to CUR (0.31 µg/ml, Fig. S5A), in accordance with a previous 40 
study using Indole-3-butyric acid loaded in MCM-41.23 MCM-
41-CUR PM showed solubility similar to CUR (0.36 µg/ml). The 
enhanced solubility of curcumin in MCM-41-CUR is attributed to 
the encapsulation in nanopores based on Ostwald – Freundlich 
equation where the solubility enhancement is related to particle 45 
size.27 This augmented solubility of curcumin from MCM-41-
CUR is also observed from in vitro release profile performed in 
0.5% Sodium lauryl sulphate (SLS) as the dissolution medium 
(Fig. S5B). After 1 h, the release for CUR, MCM-41-CUR and 
MCM-41-CUR PM was 0.25%, 0.67% and 0.29% respectively. 50 
The drug release profile increased slowly for MCM-41-CUR 
reaching 28.5% after 72 h whereas the drug release for CUR and 
MCM-41-CUR PM was just 8.9% and 9%, respectively. The 
faster and higher release amount of CUR from MCM-41-CUR 
should be attributed to the formation of CUR nano-aggregates in 55 
the pore channels of MCM-41. 
 Taking advantage of the improved solubility and in vitro 
release profile, cell cytotoxicity studies using MTT assay on 
SCC-25 cell line was conducted in triplicate (See ESI, In vitro 
Cytotoxicity Assay and Table S2 for % cell viability with standard 60 
deviation). MCM-41 showed no cytotoxicity even after 72 h 
confirming earlier reports of silica nanoparticles to be a better 
drug carrier system.28 MCM-41-CUR treated cells showed dose 
and time-dependent higher cell cytotoxicity compared to CUR 
and MCM-41-CUR PM (Fig. 1A). For example, the cell viability 65 
from CUR (46%) and MCM-41-CUR (37%) is similar at 45 ppm 
dose after 24 h but higher than that of MCM-41-CUR PM (67%). 
Cytotoxicity from CUR reaches almost maximum activity 
showing no increase in cytotoxicity at 48 and 72 h. On the other 
hand, the cell viability from MCM-41-CUR decreases with 70 
exposure time showing 11% and only 2% at 48 and 72 h, 
respectively. The superior cytotoxicity of MCM-41-CUR could 
be attributed to enhanced and sustained release of curcumin from 
the MCM-41-CUR as demonstrated from the in vitro dissolution 
studies (Fig S5B). Moreover, it was demonstrated that MSNs 75 
upto 250 µg/ml did not affect cell viability when studied in HEK 
293 cells.29 As there is no report using curcumin nano-
formulation in SCC-25 cell line, we compared our results with 
studies performed in MCF-7 cell line using curcumin 
nanospheres or solid lipid nanoparticles and found the 80 
cytotoxicity observed in our studies is comparable.7, 30 
 We further studied the down-regulation of PcG proteins – 
enhancer of zeste homolog 2 (EzH2) and B lymphoma Mo-MLV 
insertion region 1 homolog (Bmi-1) by conducting Western blot 
analysis on SCC-25 cell line (Fig 1B). The glyceraldehyde-3-85 
phosphate dehydrogenase (GAPDH) was used as an internal 
loading control in the analysis. We observed that CUR and 
MCM-41-CUR increases activation of caspase-3 through 
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generation of cleaved caspase-3 resulting in enhanced cell 
apoptosis. MCM-41-CUR mediated suppression of PcG proteins 
and protease mediated apoptosis are the key events in SCC-25 
cell death. The efficacy of MCM-41-CUR was clearly evident 
from the dramatic reduction in EzH2 level compared to CUR. 5 
This higher efficacy could be due to the enhanced endocytosis as 
observed from the higher silica content in SCC-25 cells carrying 
curcumin cargo in the cells (Fig. S6) and time-dependent 
controlled release of curcumin from MCM-41-CUR. Though 
there are not many reports focusing on the impact of curcumin 10 
nano-formulation on PcG proteins, our observation is in line with 
previous report studying the effect of free curcumin on down-
regulation of EzH2 expression in human breast cancer MDA-
MB-435 cells.31     
 In summary, we have demonstrated a simple and efficient 15 
technique for curcumin encapsulation in the nanopores of MCM-
41 type MSNs. This strategy leads to improved aqueous 
solubility, enhanced drug release, and high cellular delivery 
efficiency of curcumin. Consequently, compared to the pure drug, 
curcumin encapsulated in MCM-41 possesses enhanced cytotoxic 20 
effect, which is linked with the inhibition of PcG proteins and 
activation of caspase-3. This work provides a simple but efficient 
method to design new curcumin based nano-formulations to 
improve its therapeutic efficacy. 
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